SEC Form 4 · accession 0001567619-19-006759
RESMED INC · RMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael J. Farrell
Officer — Chief Executive Officer
Period of report
Mar 11, 2019
Accepted (ET)
Mar 12, 2019 · 8:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000943819
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| ResMed Common Stock | Mar 11, 2019 | M | 6,651 | $43.63 | A | 292,933 | D | |
| ResMed Common StockF2 | Mar 11, 2019 | S | 6,651 | $101.05 | D | 286,282 | D | |
| ResMed Common Stock | holding | — | — | — | 10,340 | I | Lisette and Michael Farrell Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ResMed Common Stock OptionsF3 | $43.63 | Mar 11, 2019 | M | 6,651 | D | Mar 1, 2014 | Mar 1, 2020 | ResMed Commmon Stock | 6,651 | 73,157 | D |
Explanation of responses
- F1The transaction was conducted under a Rule 10b5-1 plan.
- F2This transaction was executed in multiple trades at prices ranging from $100.89 to $101.20. The price reported above reflects the weighted average sale price.
- F3Represents date options first become exercisable. Options vest 1/3 annually.